Avvierà collaborazioni per la cura di malattie neurodegenerative
Search Results for: La malattia di Parkinson non è una, ma due malattie
Here's what we've found for you
Diagnosi, trattamento e cura della meningite
Sono state pubblicate dall’WHO le linee guida sul trattamento e cura della […]
Esperti, 'I pazienti oncologici devono vaccinarsi, stop alla diffidenza ingiustificata'
Al via il tour di Aiom in 10 Regioni per promuovere le immunizzazioni. Proteggono da gravi malattie e complicanze
Test sangue semplice e low cost per diagnosi precoce Parkinson
Individua la malattia prima che compaiano i sintomi
Impact of hypersexuality on spousal carers of patients with Parkinsons disease and frontotemporal dementia: a qualitative study
Objectives
Hypersexuality involves an inability to control intense, recurring sexual impulses, resulting in repetitive sexual behaviours. It frequently manifests in patients with neurodegenerative disorders such as Parkinson’s disease (PD) and dementia. Using a qualitative approach, this study aims to explore the impact of hypersexuality on spousal carers of patients with PD and dementia.
Design
Qualitative study using semistructured interviews and thematic analysis.
Setting
This study was conducted in secondary care settings, including movement disorder and dementia clinics, as well as through patient support organisations. Participants were recruited from multiple centres across the UK. Interviews were conducted in a clinical research setting.
Participants
Eight spousal carers (five caring for patients with PD, three for patients with dementia) participated in the study. Participants were selected based on their role as primary carers and their experience managing hypersexuality in their partners.
Results
The thematic analysis identified 12 themes: manifestations, sexual practices, impact, control, emotional formulations, beliefs in causes of hypersexuality and attributions, relationship with the partner, dealing with hypersexuality, coping with hypersexuality, self-image, stigma and professional help-seeking. Hypersexuality altered patients’ sexual cognitions and behaviours, causing distress and strain on carers’ mental health and marital life. Carers struggled to cope with their partners’ hypersexuality, facing emotional burden and barriers to seeking professional help.
Conclusions
Hypersexuality significantly impacts spousal carers of patients with PD and dementia, affecting their emotional well-being and relationships. Healthcare professionals should recognise and address hypersexuality’s psychological and relational consequences. Psychoeducation, support groups and tailored interventions for patients and carers are recommended to alleviate emotional distress. Future research should explore the broader familial impact of hypersexuality and develop effective management strategies.
Dal vaccino alle staminali, su cosa si punta contro il Parkinson
L’11 la giornata mondiale sulla malattia che continua a crescere
Dal vaccino alle staminali, su cosa si punta contro il Parkinson
L’11 la giornata mondiale sulla malattia che continua a crescere
Una proteina coinvolta nel morbo di Parkinson provoca anche il cancro della pelle
Una nuova ricerca condotta dall’Oregon Health & Science University ha […]
Active group-based performing arts interventions in Parkinsons disease: an updated systematic review and meta-analysis
Objectives
To assess the evidence for active group-based performing arts interventions for people with Parkinson’s disease (PD).
Setting
Scholarly literature (published in English) from any country or countries (last search February 2025). This systematic review was not registered and received no funding.
Data sources
Five bibliographic databases: AMED (Ebsco), APA PsycINFO (Ovid), CINAHL (Ebsco), EMBASE (Ovid) and MEDLINE (Ovid), plus supplementary searches.
Primary and secondary outcome measures
Eligible studies used a quantitative design to assess the benefit of active group-based performing arts interventions on quality of life, functional communication, speech, motor function and cognitive status in PD. The risk of bias was assessed using the SURE, University of York Centre for Reviews and Dissemination and Newcastle-Ottawa Scale checklists. Data were synthesised using narrative synthesis and random-effects meta-analysis.
Results
A total of 94 studies were included: 2453 people with PD (mean age 68 years, 55% male) from 18 countries. Narrative synthesis supported nine combinations of performing arts modalities and outcome domains, including a benefit for dance on motor function (supported by 50 out of 54 studies), dance on quality of life (supported by 24 out of 37 studies) and singing on speech (supported by 17 out of 20 studies). Meta-analysis supported five combinations of performing art modalities, comparators and outcomes, including a clinically significant benefit for PD-specific dance versus usual care PDQ-39, MD –7.81, 95% CI –11.87 to –3.75 and tango-based dance versus usual care on UPDRS-III, MD –9.89, 95% CI –16.65 to –3.13.
Conclusions
Evidence from both the narrative synthesis and the meta-analysis supports a benefit for some combinations of performing arts modalities and outcomes. Limitations of the evidence base included differences in comparators and outcomes, heterogeneity, lack of control arms and male underrepresentation. Future studies should compare the effectiveness of different performing arts modalities, assess functional communication and consider clinical significance.
Uno studio di 5 anni e 5,3 milioni su 3 malattie neuromuscolari
Con fondi di Telethon e della Fondazione Cariparo
Uno studio di 5 anni e 5,3 milioni su 3 malattie neuromuscolari
Con fondi di Telethon e della Fondazione Cariparo
Uno studio di 5 anni e 5,3 milioni su 3 malattie neuromuscolari
Con fondi di Telethon e della Fondazione Cariparo
Schillaci, Made in Italy significa prodotti qualità e sicuri
Controlli cruciali,riemerse in Europa malattie credute eradicate
Screening neonatale, 'la burocrazia blocca l'ampliamento ad altre malattie'
Uniamo, ‘decreto Lea ancora fermo. Intanto i bambini muoiono’
Alzheimer, la stimolazione magnetica dimezza la progressione della malattia
Disponibili i risultati del primo trial clinico dopo 52 settimane
Alzheimer, la stimolazione magnetica dimezza la progressione della malattia
Disponibili i risultati del primo trial clinico dopo 52 settimane